TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Files An 8-K Other Events
Item 8.01
|
Other Events. |
On February 22, 2017, TRACON Pharmaceuticals, Inc. (the Company)
entered into a Manufacturing Agreement (the Manufacturing
Agreement) with Lonza Biologics Tuas Pte Ltd (Lonza), for the
long term manufacture and supply of TRC105, the Companys lead
drug product candidate.On May 24, 2017, the Company and Lonza
entered into Amendment No. 1 to the Manufacturing Agreement (the
Amendment) to define certain specifications and territories as
required by the Manufacturing Agreement.
The foregoing is only a summary of the provisions of the
Amendment and is qualified in its entirety by the terms of the
Amendment, a copy of which is attached as Exhibit 99.1 hereto.
|
Item 9.01 |
Financial Statements and Exhibits. |
|
(d) |
Exhibits. |
|
99.1 |
Amendment No. 1 to the Manufacturing Agreement between |
About TRACON Pharmaceuticals, Inc. (NASDAQ:TCON)
TRACON Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (wet AMD) and fibrotic diseases. The Company’s research focuses on antibodies that bind to the endoglin receptor, which is essential to angiogenesis (the process of new blood vessel formation) and a contributor to fibrosis (tissue scarring). The Company’s lead product candidate, TRC105, is an endoglin antibody that is being developed for the treatment of multiple solid tumor types in combination with inhibitors of the vascular endothelial growth factor (VEGF) pathway. TRC205 is being developed for the treatment of fibrotic disease. The Company is also developing TRC102, a small molecule that is in clinical development for the treatment of lung cancer and glioblastoma. TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Recent Trading Information
TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) closed its last trading session 00.00 at 2.85 with 80,341 shares trading hands.